CR11473A - Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria - Google Patents

Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria

Info

Publication number
CR11473A
CR11473A CR11473A CR11473A CR11473A CR 11473 A CR11473 A CR 11473A CR 11473 A CR11473 A CR 11473A CR 11473 A CR11473 A CR 11473A CR 11473 A CR11473 A CR 11473A
Authority
CR
Costa Rica
Prior art keywords
treatment
cis
multiple sclerosis
mielitis
dihidrotetrabenazine
Prior art date
Application number
CR11473A
Other languages
English (en)
Inventor
John Duffield
Original Assignee
Bioval Lab Internat Barbados Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioval Lab Internat Barbados Srl filed Critical Bioval Lab Internat Barbados Srl
Publication of CR11473A publication Critical patent/CR11473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion estipula un compuesto para usar en el tratamiento de la esclerosis multiple donde ele compuesto es una 3, 11b-cis dihidrotetrabenazina de formula o una de sus sales farmaceuticas aceptables.
CR11473A 2007-11-02 2010-06-02 Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria CR11473A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0721669.0A GB0721669D0 (en) 2007-11-02 2007-11-02 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CR11473A true CR11473A (es) 2010-11-11

Family

ID=38834835

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11473A CR11473A (es) 2007-11-02 2010-06-02 Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria

Country Status (18)

Country Link
US (1) US20110039877A1 (es)
EP (1) EP2207551A1 (es)
JP (1) JP2011502977A (es)
KR (1) KR20100074234A (es)
CN (1) CN101932323A (es)
AU (1) AU2008320603A1 (es)
CA (1) CA2702134A1 (es)
CO (1) CO6321285A2 (es)
CR (1) CR11473A (es)
EC (1) ECSP10010145A (es)
GB (1) GB0721669D0 (es)
IL (1) IL204990A0 (es)
MX (1) MX2010003980A (es)
NI (1) NI201000047A (es)
NZ (1) NZ584846A (es)
RU (1) RU2010116859A (es)
WO (1) WO2009056885A1 (es)
ZA (1) ZA201003037B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744456A (zh) 2010-06-01 2015-07-01 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2015112707A1 (en) 2014-01-27 2015-07-30 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
LT3368534T (lt) 2015-10-30 2021-04-12 Neurocrine Biosciences, Inc. Valbenazino ditozilatas ir jo polimorfai
PT3394057T (pt) 2015-12-23 2022-04-21 Neurocrine Biosciences Inc Método sintético para a preparação de 2-amino-3-metilbutanoato de di(4-metilbenzenesulfonato) (s)-(2r,3r,11br)-3-isobutil-9,10-dimetoxi-2,3,4,6,7,11bhexaidro-1h-pirido[2,1,-a]lsoquinolin-2-ilo
US20200093808A1 (en) 2017-01-27 2020-03-26 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019074492A1 (en) 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
US20070037800A1 (en) * 2005-06-23 2007-02-15 Envivo Pharmaceuticals, Inc. Method of treating neurological disorders using clotrimazole and derivatives thereof
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CA2702134A1 (en) 2009-05-07
ECSP10010145A (es) 2010-08-31
US20110039877A1 (en) 2011-02-17
EP2207551A1 (en) 2010-07-21
RU2010116859A (ru) 2011-12-10
JP2011502977A (ja) 2011-01-27
CN101932323A (zh) 2010-12-29
GB0721669D0 (en) 2007-12-12
IL204990A0 (en) 2010-11-30
NI201000047A (es) 2010-09-09
ZA201003037B (en) 2011-08-31
CO6321285A2 (es) 2011-09-20
WO2009056885A1 (en) 2009-05-07
KR20100074234A (ko) 2010-07-01
NZ584846A (en) 2011-07-29
AU2008320603A1 (en) 2009-05-07
MX2010003980A (es) 2010-11-09

Similar Documents

Publication Publication Date Title
CR11473A (es) Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
GT200500175A (es) Inhibidores de cetp
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
PA8774801A1 (es) Productos para el cuidado oral y metodos de uso y fabricacion de los mismos
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
ECSP11011151A (es) Compuestos purina
CR11483A (es) Inhibidores de peptido desformilasa
CO6400224A2 (es) Purificación de 1-[2-(2-4-dimetilfenilsulfanil)fenil]piperazina
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
AR056049A1 (es) 2-(2,6-dimetil-morfolin-4-il-n-[5-(6-morfolin-4-il-4-oxo-4h-piran-2-il)-9h-tioxanten-2-il]-acetamida,como inhibidor de la quinasa atm
CR20120171A (es) Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi) fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cáncer resistente al agente antimitótico
CR11859A (es) Composición y proceso-356
CO6361988A2 (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
UY31022A1 (es) Uso de fungicidas para el tratamiento de micosis en peces
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
UY30788A1 (es) Compuestos quimicos
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.
MX350019B (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-bencimidaz ol-4-carboxamida.
CR11613A (es) Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)